Russell Investments Group Ltd. Increases Stock Holdings in Merck & Co., Inc. $MRK

Russell Investments Group Ltd. lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 2.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,578,024 shares of the company’s stock after purchasing an additional 51,393 shares during the quarter. Russell Investments Group Ltd.’s holdings in Merck & Co., Inc. were worth $331,931,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Orca Investment Management LLC grew its holdings in shares of Merck & Co., Inc. by 5.8% in the second quarter. Orca Investment Management LLC now owns 19,257 shares of the company’s stock valued at $2,475,000 after purchasing an additional 1,061 shares in the last quarter. TFR Capital LLC. lifted its holdings in Merck & Co., Inc. by 4.8% during the 2nd quarter. TFR Capital LLC. now owns 6,757 shares of the company’s stock worth $868,000 after buying an additional 309 shares in the last quarter. OakTrust Wealth Advisors LLC acquired a new stake in Merck & Co., Inc. during the 2nd quarter worth approximately $207,000. Maridea Wealth Management LLC purchased a new position in Merck & Co., Inc. in the 2nd quarter valued at approximately $220,000. Finally, Ridgecrest Wealth Partners LLC boosted its position in Merck & Co., Inc. by 2.4% in the 2nd quarter. Ridgecrest Wealth Partners LLC now owns 7,002 shares of the company’s stock valued at $900,000 after buying an additional 164 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on MRK. Wells Fargo & Company boosted their price target on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday. The Goldman Sachs Group boosted their target price on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday. Finally, JPMorgan Chase & Co. upped their price target on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $144.10.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. This represents a 21.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock valued at $29,977,783 over the last 90 days. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Trading Down 0.1%

NYSE MRK opened at $152.43 on Monday. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $154.49. The firm has a 50 day moving average of $128.09 and a two-hundred day moving average of $121.29. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The stock has a market capitalization of $376.07 billion, a PE ratio of 121.94, a price-to-earnings-growth ratio of 6.40 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company’s revenue was up 5.1% on a year-over-year basis. During the same period last year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.